Clinical TrialMay 21, 2026, 06:08 AM
Immix Biopharma's NXC-201 Trial Achieves 95% CR Rate in AL Amyloidosis
AI Summary
Immix Biopharma announced a significant update from its Phase 2 NEXICART-2 NXC-201 clinical trial for relapsed/refractory AL Amyloidosis, reporting a 95% complete response (CR) rate among the first 20 patients. All four MRD-negative patients previously highlighted at ASH 2025 have now converted to CR, with no relapses observed to date. The company plans to initiate a multi-center, randomized Phase 3 trial for NXC-201 in newly diagnosed AL Amyloidosis patients in the first half of 2027, with the next NEXICART-2 update expected in late September 2026.
Key Highlights
- NEXICART-2 NXC-201 trial shows 95% complete response (CR) rate (19/20 patients) in relapsed/refractory AL Amyloidosis.
- All four MRD-negative patients announced at ASH 2025 converted to CR.
- No relapses observed to date for patients who reached CR.
- All CRs were reached within one year of follow-up post-dosing.
- MRD-negativity 10-5 achieved within 30 days for all MRD-negative patients.
- 17 of 20 patients showed rapid normalization of diseased light chains with median time to initial response of 7 days.
- Next NEXICART-2 update expected in late September 2026.
- Phase 3 trial of NXC-201 in newly diagnosed AL Amyloidosis patients planned for H1 2027.
Price Impact
More from IMMX